Skip to main content

Table 2 Change from baseline at week 24 and week 52 for patient-reported outcomes

From: Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment

PRO measurea (95% CI)

 

Week 24

  

Week 52

 
 

MTX (N = 210)

Baricitinib 4 mg (N = 159)

Baricitinib 4 mg + MTX (N = 215)

MTX (N = 210)

Baricitinib 4 mg (N = 159)

Baricitinib 4 mg + MTX (N = 215)

Physical Function (HAQ-DI)

− 0.74 (− 0.83, − 0.66)

− 1.04 (− 1.14, − 0.95)***

− 1.03 (− 1.11, − 0.95)***

− 0.71 (− 0.79, − 0.62)

− 0.99 (− 1.08, − 0.89)***

− 1.06 (− 1.14, − 0.97)***

Patient’s Global Assessment of Disease Activity (PtGA)

− 31 (− 34, − 27)

− 41 (− 45, − 38)***

− 40 (− 43, − 37)***

− 29 (− 32, − 26)

− 40 (− 44, − 37)***

− 43 (− 46, − 39)***

Patient’s assessment of pain

− 30 (− 33, − 27)

− 41 (− 45 − 37)***

− 41 (− 44, − 38)***

− 31 (− 34, − 27)

− 40 (− 44, − 37)***

− 43 (− 47, − 40)***

FACIT-F

8.9 (7.6, 10.1)

13.3 (11.8, 14.7)***

12.2 (11.0, 13.5)***

8.9 (7.6, 10.2)

11.7 (10.2, 13.1)**

12.6 (11.4, 13.9)***

MJS Duration, median change from baseline

− 35.0 (− 55.0, − 25.0)

− 50.0 (− 60.0, − 30.0)

− 59.0 (− 85.0, − 40.0)**

− 40.0 (− 55.0, − 30.0)

− 55.0 (− 60.0, − 40.0)

− 60.0 (− 80.0, − 50.0)**

Worst Joint Pain NRS

− 2.8 (− 3.2, − 2.5)

− 4.0 (− 4.3, − 3.6) ***

− 4.0 (− 4.3, − 3.7)***

− 3.0 (− 3.4, − 2.7)

− 3.9 (− 4.3, − 3.6)***

− 4.1 (− 4.4, − 3.8)***

Worst Tiredness NRS

− 2.1 (− 2.5, − 1.8)

− 3.1 (− 3.5, − 2.7)***

− 3.0 (− 3.3, − 2.7)***

− 2.2 (− 2.5, − 1.8)

− 3.0 (− 3.4, − 2.6)**

− 2.9 (− 3.3, − 2.6)**

EuroQol-5 Dimensions (EQ-5D)

 Health State Index Score, UK algorithm

0.200 (0.173, 0.227)

0.288 (0.257, 0.318)***

0.288 (0.261, 0.315)***

0.191 (0.161, 0.221)

0.272 (0.239, 0.306)***

0.273 (0.244, 0.303)***

 US algorithm

0.138 (0.119, 0.158)

0.199 (0.177, 0.221) ***

0.199 (0.179, 0.218) ***

0.133 (0.111, 0.154)

0.187 (0.163, 0.211)***

0.189 (0.168, 0.210)***

 Self-perceived health score

15 (12, 18)

24 (20, 27)***

22 (18, 25)**

14 (11, 18)

25 (21, 28)***

25 (22, 28)***

  1. CI confidence interval, MJS morning joint stiffness, MTX methotrexate, NRS numeric rating scale, PRO patient-reported outcomes, RA rheumatoid arthritis
  2. aData are presented as least-squares mean unless stated otherwise
  3. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001 vs. MTX